Camber launches colchicine capsules
Colchicine capsules are indicated for prophylaxis of gout flares in adults.
Camber Pharmaceuticals
Camber launches metformin hydrochloride oral solution
Metformin hydrochloride oral solution is available in 500 mg/5 mL, 16 oz. bottle.
Camber launches prucalopride tablets
Prucalopride tablets are indicated for the treatment of chronic idiopathic constipation (CIC) in adults.
Camber Pharmaceuticals launches Chlorpromazine HCl Injection, USP
Chlorpromazine HCl Injection is indicated for the treatment of schizophrenia, severe behavioral problems in children, and manic-depressive illness.
Camber launches Mycophenolate Mofetil Tablets, USP
Mycophenolate Mofetil Tablets, USP are an antimetabolite immunosuppressant indicated for the prophylaxis of organ rejection.
Camber launches Olmesartan medoxomil tablets, USP
Olmesartan medoxomil tablets, USP are indicated for the treatment of hypertension in adults and children six years of age and older, to lower blood pressure.
Camber launches generic Dacogen
Decitabine for injection is available in a 50 mg single-dose vial.
Camber launches generic Stendra
Avanafil tablets is a phosphodiesterase 5 (PDE5) inhibitor indicated for the treatment of erectile dysfunction.
Camber unveils generic Neurontin
Gabapentin oral solution is available in a 470 mL bottle with a concentration of 250 mg per 5 mL.
Camber’s readiness for DSCSA compliance
Camber is fully prepared for DSCSA compliance by November 2024.
